Clinic Disease Events Radiation Oncology 
AuntMinnie
SEPTEMBER 30, 2024
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. The researchers also tracked overall survival and rates of adverse events.
Imaging Technology
AUGUST 8, 2024
5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer. assistant professor of Gastrointestinal Radiation Oncology. “We
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
SEPTEMBER 27, 2023
milla1cf Wed, 09/27/2023 - 15:07 September 27, 2023 — The American Society for Radiation Oncology ( ASTRO ) announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
Imaging Technology
SEPTEMBER 27, 2023
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Clinical correlation, which may include histopathological evaluation, is recommended.
AuntMinnie
OCTOBER 2, 2024
Ultrasound model predicts liver disease progression. Assessment of Claimant, Clinical, and Financial Characteristics of Teleradiology Medical Malpractice Cases. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. SPECT/CT reveals heart’s response to tafamidis.
Imaging Technology
SEPTEMBER 29, 2023
The findings, which are the latest from a series of studies investigating the benefits of stereotactic body radiation therapy (SBRT) for people diagnosed with prostate cancer, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. weeks (78 Gy) or 20 fractions over four weeks (62 Gy).
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman. please insert video here.
Expert insights. Personalized for you.
119 
Let's personalize your content